Strategic Financial Concepts LLC Makes New Investment in Solventum Co. (NYSE:SOLV)

Strategic Financial Concepts LLC acquired a new stake in shares of Solventum Co. (NYSE:SOLV) in the fourth quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The institutional investor acquired 14,992 shares of the company’s stock, valued at approximately $990,000.

Several other hedge funds have also made changes to their positions in SOLV. Modus Advisors LLC acquired a new stake in Solventum during the fourth quarter worth $25,000. Copeland Capital Management LLC acquired a new stake in shares of Solventum during the 3rd quarter valued at about $26,000. Stonebridge Financial Group LLC bought a new stake in Solventum in the fourth quarter valued at about $26,000. Crews Bank & Trust acquired a new position in Solventum in the fourth quarter worth about $32,000. Finally, True Wealth Design LLC lifted its stake in Solventum by 23,550.0% during the third quarter. True Wealth Design LLC now owns 473 shares of the company’s stock worth $33,000 after purchasing an additional 471 shares during the period.

Solventum Stock Up 0.0 %

Solventum stock opened at $74.27 on Wednesday. The stock has a 50-day simple moving average of $70.82 and a 200 day simple moving average of $68.76. The company has a quick ratio of 0.83, a current ratio of 1.15 and a debt-to-equity ratio of 2.45. Solventum Co. has a 12-month low of $47.16 and a 12-month high of $96.05.

Analyst Ratings Changes

SOLV has been the subject of a number of recent research reports. Mizuho initiated coverage on Solventum in a report on Wednesday, December 4th. They issued a “neutral” rating and a $70.00 target price for the company. Piper Sandler increased their price objective on Solventum from $71.00 to $75.00 and gave the stock a “neutral” rating in a research note on Friday, November 8th. Finally, Morgan Stanley boosted their target price on shares of Solventum from $60.00 to $73.00 and gave the company an “equal weight” rating in a research note on Monday, November 11th. One analyst has rated the stock with a sell rating, nine have assigned a hold rating and one has issued a buy rating to the company’s stock. Based on data from MarketBeat.com, Solventum currently has a consensus rating of “Hold” and an average target price of $68.29.

About Solventum

Solventum Corporation, a healthcare company, engages in the developing, manufacturing, and commercializing a portfolio of solutions to address critical customer and patient needs. It operates through four segments: Medsurg, Dental Solutions, Health Information Systems, and Purification and Filtration.